Kersten L, Bräunlich H, Keppler B K, Gliesing C, Wendelin M, Westphal J
Institute of Pharmacology and Toxicology, Friedrich Schiller University, Jena, Germany.
J Appl Toxicol. 1998 Mar-Apr;18(2):93-101. doi: 10.1002/(sici)1099-1263(199803/04)18:2<93::aid-jat472>3.0.co;2-w.
The nephrotoxicity of three platinum (CPL, KP734, KP735) and three ruthenium coordination complexes (KP418, KP692, KP1019) was tested in rats in comparison to cisplatin (CP). Renal functional changes (excretion of water, protein, p-aminohippurate (PAH) and osmolytes) were not observed after the administration of 10% of the LD450 of the compounds given twice a week for up to 5 weeks. After a relatively high single dose of the substances (50% of the LD50), signs of nephrotoxicity on the day of maximal renal damage decreased in the following order: CP, KP418, CPL, KP734, KP735, KP692 and KP1019. In comparison to CP, proteinuria was significantly lower after the administration of any of the compounds, especially KP692 and KP1019. Neither renal lipid peroxidation (TBARS) nor glutathion status (GSH, GSSG) was affected. In summary, KP735 in the group of platinum complexes and KP1019 in the ruthenium group had the lowest nephrotoxicity. Other investigators have shown that all complexes induced anti-neoplastic activity under analogous experimental conditions.
将三种铂(CPL、KP734、KP735)和三种钌配位络合物(KP418、KP692、KP1019)的肾毒性与顺铂(CP)相比,在大鼠身上进行了测试。每周两次给予化合物LD450的10%,持续5周,未观察到肾功能变化(水、蛋白质、对氨基马尿酸(PAH)和渗透溶质的排泄)。给予相对高的单次剂量物质(LD50的50%)后,在最大肾损伤当天,肾毒性迹象按以下顺序降低:CP、KP418、CPL、KP734、KP735、KP692和KP1019。与CP相比,给予任何一种化合物后蛋白尿均显著降低,尤其是KP692和KP1019。肾脂质过氧化(TBARS)和谷胱甘肽状态(GSH、GSSG)均未受影响。总之,铂络合物组中的KP735和钌组中的KP1019肾毒性最低。其他研究人员表明,在类似实验条件下,所有络合物均诱导抗肿瘤活性。